Reduced monocyte proportions and responsiveness in convalescent COVID-19 patients

Introduction The clinical manifestations of acute severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19) suggest a dysregulation of the host immune response that leads to inflammation, thrombosis, and organ dysfunction. It is less clear whether these dysregulated processes persist during the convalescent phase of disease or during long COVID. We sought to examine the effects of SARS-CoV-2 infection on the proportions of classical, intermediate, and nonclassical monocytes, their activation status, and their functional properties in convalescent COVID-19 patients. Methods Peripheral blood mononuclear cells (PBMCs) from convalescent COVID-19 patients and uninfected controls were analyzed by multiparameter flow cytometry to determine relative percentages of total monocytes and monocyte subsets. The expression of activation markers and proinflammatory cytokines in response to LPS treatment were measured by flow cytometry and ELISA, respectively. Results We found that the percentage of total monocytes was decreased in convalescent COVID-19 patients compared to uninfected controls. This was due to decreased intermediate and non-classical monocytes. Classical monocytes from convalescent COVID-19 patients demonstrated a decrease in activation markers, such as CD56, in response to stimulation with bacterial lipopolysaccharide (LPS). In addition, classical monocytes from convalescent COVID-19 patients showed decreased expression of CD142 (tissue factor), which can initiate the extrinsic coagulation cascade, in response to LPS stimulation. Finally, we found that monocytes from convalescent COVID-19 patients produced less TNF-α and IL-6 in response to LPS stimulation, than those from uninfected controls. Conclusion SARS-CoV-2 infection exhibits a clear effect on the relative proportions of monocyte subsets, the activation status of classical monocytes, and proinflammatory cytokine production that persists during the convalescent phase of disease.


Introduction
Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) is the causative agent of coronavirus infectious disease 19 (COVID-19) As of August 2023, it has affected over 770 million people, resulting in nearly 7 million deaths worldwide (WHO Coronavirus (COVID) dashboard).The symptoms of the disease vary from mild to severe, depending on age, gender, physical health, and other host factors.Notably, a dysregulated host immune response is observed in COVID-19 patients, leading to complications like hyperinflammation, thrombosis, and organ damage (1,2).Cytokine storm, characterized by elevated levels of circulating cytokines and hyperactivation of immune cells (3,4), and coagulopathy, an alteration in the normal blood clotting process (5,6), are the two major mechanisms contributing to COVID-19 pathogenesis.Myeloid cells, including circulating monocytes and tissue macrophages, are pivotal in mediating these pathologies.
The fate of monocytes during the convalescent phase of COVID-19 is less well understood.In some studies, patients who fully recovered from acute COVID-19 infection were found to have increased circulating non-classical monocytes and decreased classical monocytes during convalescence (19-21).In addition, these studies showed that monocytes in convalescent individuals display increased levels of inflammatory genes (21-24), antigen presentation molecules, including HLA-DQA and HLA-DPA (20), and the activation marker CD169 (21).However, other studies have demonstrated a decrease in monocyte percentages in convalescent individuals including those who had severe disease (25,26) or comorbid conditions (27).While a growing body of research has shed light on monocyte behavior during the convalescent phase, contrasting findings underscore the need for more detailed studies to unravel these complexities.
Similar findings have been seen with long COVID, a heterogeneous syndrome characterized by persistent significant health issues lasting, recurring, or developing three months after initial infection (28)(29)(30)(31).Although the mechanisms driving long COVID are poorly understood (32), myeloid cells are thought to play a significant role.A number of studies have demonstrated that patients experiencing long COVID have persistently elevated levels of IFN-b, IFN-L1, IFN-g, TNF-a, IL-1b, IL-6, IL-10, IL-12, and IL-17 (33)(34)(35)(36); however, more recent studies have demonstrated that long COVID is associated with cytokine deficiencies (37).In addition, Phetsouphanh et al. described elevated numbers of circulating activated monocytes and plasmacytoid dendritic cells (pDCs) (36).Despite these studies, the contribution of myeloid cells in long COVID, much like in the convalescent phase of the disease, are not well understood.
To further clarify the role and behavior of monocytes post-COVID, our study used a comprehensive approach involving multiparameter flow cytometry and functional assays.We focused on the phenotypic and functional characteristics of monocytes in the circulating blood from convalescent COVID-19 patients.Specifically, we examined the proportions of classical, intermediate, and non-classical monocytes, evaluated their activation status in response to bacterial lipopolysaccharide (LPS), and examined their ability to produce inflammatory cytokines.Our studies revealed several phenotypic and functional alterations in monocytes during the convalescent phase of SARS-CoV-2 infection.

Study subjects
We obtained donor blood samples from individuals who were recruited under University of Utah Institutional Review Board (IRB) protocol 131664.These individuals were recruited from Salt Lake City, UT and the surrounding metropolitan area between May of 2020 and December of 2021.Informed consent was obtained from all individual participants included in the study.The deidentified specimens were blinded during collection and analysis.Whole blood samples were drawn from 18 convalescent COVID-19 patients and 31 healthy individuals in parallel.The clinical samples were obtained from convalescent patients who exhibited a mild form of the disease and did not require hospitalization.For convalescent patients, specimens were collected approximately two to four weeks after disease onset.Donors reported no symptoms at the time of sample collection.1).SARS-CoV-2 infection was assessed by one or more immunologic (Abbott Architect SARS-CoV-2 IgG, Euroimmun Anti-SARS-CoV-2 ELISA, or Siemens SARS-CoV-2 IgG) (38) or molecular assays.

Blood samples
Fifteen mL of whole blood was collected by phlebotomycertified research staff into two BD Vacutainer EDTA Additive Blood Collection Tubes.Tubes were gently inverted eight times to mix the blood and EDTA and were then centrifuged at 150 x g for 20 minutes at room temperature.Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll density gradient (Histopaque-1077, Sigma), and were cryopreserved in 1 ml aliquots in 90% complete culture media [RPMI 1640 with 10% Fetal Bovine Serum (FBS)] and 10% dimethyl sulfoxide (DMSO) in sterile cryovials.PBMCs were stored in liquid nitrogen prior to use.

Isolation of peripheral blood monocytes
Total monocytes were isolated by negative selection using the EasySep Human Monocyte Enrichment Kit without CD16  Depletion (StemCell Technologies) using the manufacturer's instructions.Briefly, PBMCs were resuspended at 5 x 10 7 cells/mL in isolation buffer (PBS with 2% FBS and 1 mM EDTA) and incubated with the enrichment cocktail (50 mL/mL) at 4°C for 10 minutes.Next, vortexed magnetic particles were added, and the sample was mixed and incubated at 4°C for 5 minutes.Isolation media was then added to a final volume of 2.5 mL and the sample was placed in an EasySep magnet at room temperature for 2.5 minutes.The enriched cell suspension (non-monocytes) was poured off into a new tube, and the remaining cells (monocytes) were washed three times with isolation buffer.The tube was then removed from the magnet and purified monocytes were decanted into a new tube for use.

Determination of cytokine concentration
Isolated monocytes were plated at 1x10 5 cells/well in 96-well plates in 200 mL of complete culture medium (RPMI 1640 with 10% FBS, 100 U/mL penicillin, 100 mg/mL streptomycin, and 0.29 mg/ mL L-glutamine).Monocytes were treated with E. coli LPS (Invivogen) at 100 ng/mL.After 18 hours, the plates were briefly centrifuged, and cell-free supernatant was harvested for analysis.TNFa and IL-6 were measured in culture supernatant by ELISA (R&D Systems) according to the manufacturer's instructions.

Statistical analysis
Demographic data of donors were analyzed for statistical significance using either unpaired t-test with Welch's correction or Fisher's exact test.Flow cytometry data and individual cytokine values for uninfected and convalescent COVID-19 (unpaired) specimens were analyzed for statistical significance using Mann-Whitney tests.Flow cytometry data and individual cytokine values for untreated and LPS-treated (paired) specimens were analyzed for statistical significance using Wilcoxon rank tests.The level of significance was determined as p < 0.05.Statistical analyses and graphic presentation were performed using Prism 9.01 software (GraphPad Software, Inc., San Diego, California).

Study population description
Peripheral blood specimens were obtained from uninfected individuals and from convalescent patients who exhibited a mild form of the disease.Specimens were collected between May 2020 and January 2021, during the initial SARS-CoV-2 outbreak in the United States.The median age of the participants was 36 years (range 19-65) for uninfected subjects (n=31) and 42.5 years (range 19-71) for convalescent COVID-19 subjects (n=18).None of the participants had received a COVID vaccine at the time of sample collection.All individuals from the convalescent COVID-19 population had mild symptoms, including fever, headache, rhinorrhea, sore throat, cough, fatigue, and/or myalgias, which did not require medical intervention or hospitalization during illness.Their symptoms resolved within two weeks of disease onset and specimens were collected approximately two to four weeks after disease onset.The convalescent patients and uninfected donors reported no symptoms at the time of sample collection.Participant characteristics, including self-reported co-morbidities, are listed in Table 1.

The proportion of circulating monocytes is decreased in convalescent COVID-19 patients
To determine the effect of COVID-19 infection on blood monocytes during the convalescent stage of disease, peripheral blood mononuclear cells were isolated from convalescent COVID-19 patients (n=18) and uninfected controls (n=31) and were analyzed by flow cytometry.The gating strategy for identifying total monocytes, total lymphocytes, myeloid dendritic cells (mDCs), and plasmacytoid dendritic cells (pDCs) is shown in Supplementary Figure S1.We found that the percentage of total circulating monocytes (relative to total PBMCs) was lower in convalescent COVID-19 patients (23.7%) compared to uninfected controls (38.5%)(Figure 1A).Conversely, the percentage of lymphocytes was increased in the convalescent population (70% in COVID-19 patients vs. 54.5% in controls) (Figure 1B).There was no significant difference in the percentages of mDCs or pDCs between the two populations (Figures 1C, D).The increase in lymphocytes in the convalescent population was driven by an increase in T cells, without a significant difference in the percentages of B cells between the two populations (Figure 2).There was a slight, but significant, decrease in the percentage of NK cells in convalescent COVID-19 patients (Figure 2C).These findings are consistent with prior studies demonstrating a decrease in circulating monocytes during convalescent COVID-19 infection (25,26).
Monocyte subsets including classical monocytes (CD14+ CD16-), intermediate monocytes (CD14+ CD16+), and nonclassical (CD14 lo CD16+) were defined by CD14 and CD16 expression within the total monocyte population (Supplementary Figure S1).Whereas the number of classical monocytes was unchanged between the uninfected and convalescent groups (Figure 3A), the percentage of intermediate and non-classical monocytes were significantly decreased in convalescent patients compared to uninfected donors (2.8% vs. 3.9% and 1.5% vs. 2.6%, respectively) (Figures 3B, C).Together, these observations suggest that circulating monocyte percentages decrease in convalescent patients, with significant decreases in intermediate and nonclassical monocytes.

Expression of monocyte activation markers is altered in convalescent COVID-19 patients
To further investigate differences in monocyte activation between the study populations, we assessed the expression of a number of activation markers including: CD4, a glycoprotein expressed at low levels on the surface of monocytes which may stimulate cytokine expression and differentiation to macrophages (39) and which is downregulated in response to LPS stimulation (40, 41); CD56, an adhesion molecule that is expressed at high levels on monocytes in inflammatory conditions (42-44), including severe COVID-19 infection (45,46); CD69, a type II C-lectin receptor upregulated on monocytes in response to stimulation (47); CD83, a transmembrane protein involved in the regulation of immune responses (48); and CD86, a co-stimulatory molecule expressed in monocytes whose expression can be altered by LPS treatment (49).We chose to activate monocytes with E. coli LPS, which is considered an initiator of classical activation in monocytes and leads to the production of proinflammatory cytokines and the generation of other immune mediators such nitric oxide (reviewed in reference 50).The gating strategy for identifying total monocytes and monocyte subsets for the examination of activation markers is shown in Supplementary Figure S2.
When comparing classical monocytes from convalescent COVID-19 patients (n=18) and uninfected controls (n=31), we found no significant differences in the percentages of cells expressing bright (T-cell intensity) CD4, CD56, CD69, CD83, or CD86 in the absence of LPS stimulation (Figure 4).The expression patterns of these markers observed in response to LPS stimulation in these two populations were more complex.In response to stimulation with LPS, we found a statistically significant increase in the percentage of classical monocytes CD56 and CD83, a significant decrease in the percentage of classical monocytes expressing CD69 and CD86, and no change in the percentage of classical monocytes expressing bright CD4 in uninfected control subjects (Figure 4).In contrast, in convalescent COVID-19 patients, LPS treatment led to a statistically significant increase in the percentage of classical monocytes expressing bright (T-cell intensity) CD4 and CD83, a decrease in the percentage of classical monocytes expressing CD86, and no change in the percentage of classical monocytes expressing CD56 or CD69 from convalescent COVID-19 patients in response to LPS (Figure 4).When directly comparing LPS-stimulated classical monocytes from convalescent COVID-19 patients to those from uninfected subjects, there was a statistically significant increase in the percentage of cells expressing bright CD4 and CD69, a significant decrease in the percentage of cells expressing CD56, and no difference in the Unlike classical monocytes, which showed a complex pattern of activation marker expression, intermediate monocytes demonstrated uniformly decreased expression of bright CD4, CD56, CD69, CD83, and CD86 in response to stimulation with LPS (Figure 5).This was true for both convalescent and uninfected subjects.In addition, there were no significant differences in any of the activation markers tested when comparing intermediate monocytes from convalescent and uninfected populations, either at baseline or with LPS stimulation (Figure 5).The differences in activation marker expression between classical and intermediate monocytes in response to LPS stimulation is somewhat surprising given that both monocyte populations express CD14, which is necessary for binding LPS (51).These observed differences may result from differential expression of other components of LPS signaling, such as MD2 and TLR4, or downstream effector molecules.
In contrast to classical and intermediate monocytes, which showed no difference in baseline expression of CD56, a higher percentage of non-classical monocytes from convalescent patients expressed CD56 compared to those from uninfected subjects in the absence of LPS stimulation (Supplementary Figure S3B).This was the only significant difference in non-classical monocytes between the two study populations.Non-classical monocytes from both convalescent COVID-19 patients and uninfected controls demonstrated decreased CD56 and CD86 expression in response to LPS treatment (Supplementary Figures S3Bb, S3E).In addition, the percentage of non-classical monocytes expressing bright CD4 from uninfected control subjects decreased in response to LPS (Supplementary Figure S3A) and the percentage of non-classical monocytes expressing CD83 from convalescent patients decreased in response to LPS treatment (Supplementary Figure S3D) The muted response of non-classical monocytes to LPS stimulation is not entirely surprising given that, by definition, these cells express low levels of surface CD14; however, it is possible that the stimulatory effects of LPS could be potentiated by soluble CD14 present in the total monocyte culture.
In addition, we found that LPS stimulation leads to changes in the relative proportions of classical, intermediate, and non-classical monocytes in both healthy and COVID donors.We see a significant decrease in the percentages of intermediate and nonclassical monocytes with a concurrent increase in the percentage of classical monocytes in both cohorts (Supplementary Figure S4).This may reflect a transition from one state to another or perhaps decreased viability of intermediate and non-classical monocytes.It is unlikely to reflect the preferential replication of classical monocytes, given that the treatment period with is relatively short (2-3 hours) and that the percentage of monocytes (of total PBMCs) did not change significantly in response to LPS.These findings are similar to those published by other groups who demonstrated a relative increase in classical monocytes post-treatment with LPS in an experimental model of human endotoxemia (52)(53)(54).

Expression of CD142 (tissue factor) is decreased in convalescent COVID-19 patients in response to LPS stimulation
The extrinsic coagulation cascade can be triggered by soluble or cell-surface CD142 (tissue factor).Prior studies have demonstrated increased CD142 expression in the setting of viral infections (55-58) and in response to LPS (55, 59).In addition, there is a correlation between higher levels of CD142 and COVID-19 disease severity (57, 58).Given the role of coagulopathy in COVID-19 pathogenesis, we wanted to evaluate the expression of CD142 by the various monocyte subsets in our uninfected (n=31) and convalescent COVID-19 (n=18) populations.We found that although convalescent subjects had a higher percentage of classical monocytes expressing CD142 compared to uninfected subjects (mean 0.68% vs. 0.32%, p=0.0064) at baseline, they had a significantly lower percentage of CD142expressing classical monocytes in response to LPS treatment (7.2% vs. 10.1%)(Figure 6A).This was expected given our findings demonstrating decreased activation marker expression in classical monocytes from convalescent COVID-19 patients in response to LPS stimulation (Figures 4B, C).No differences in CD142 expression were observed between intermediate monocytes or non-classical monocytes from convalescent COVID-19 patients and uninfected controls (Figures 6B, C).Similar to our findings with other activation markers, this suggests that classical monocytes from convalescent subjects are less responsive to LPS stimulation.

Expression of proinflammatory cytokines is decreased in convalescent COVID-19 patients
Finally, we wanted to determine whether there were functional differences between monocytes in convalescent COVID-19 patients (n=10) and uninfected controls (n=10).It has been shown previously that monocytes from acutely infected patients produce higher levels of proinflammatory cytokines and type I IFNs (14)(15)(16)(17)(18). Similarly, monocytes in convalescent individuals have been shown to express

levels of inflammatory genes (21-24)
. There have been conflicting reports as to whether long COVID is associated with increased levels of proinflammatory cytokines (33)(34)(35)(36) or whether it is characterized by cytokine deficiencies (37).Given these disparate study results, as well as our findings suggesting a hyporesponsive monocyte phenotype in convalescent COVID-19 patients, we wanted to determine whether monocytes from convalescent COVID-19 patients were capable of producing proinflammatory cytokines in response to stimuli.We treated purified total monocytes from uninfected and convalescent COVID-19 subjects with LPS and measured TNF-a and IL-6 production by ELISA.We found that monocytes from convalescent COVID-19 patients expressed significantly lower levels of both TNF-a (Figure 7A) and IL-6 (Figure 7B) in response to LPS stimulation, consistent with our findings regarding the expression of activation markers (Figure 4) and cellular CD142 (Figure 6).In addition, unstimulated monocytes from convalescent patients expressed less IL-6 than those from uninfected controls.Taken together, our findings suggest that monocytes from convalescent COVID-19 patients are hyporesponsive to LPS stimulation.

Discussion
Several studies examining peripheral blood from COVID-19 patients demonstrated a complex immune response in which myeloid cells play a central role (60,61).The contributions of monocytes to disease pathogenesis varies depending upon the stage of infection, and relatively little is known about their role during the convalescent stage of disease.We aimed to comprehensively analyze the phenotypic and functional changes of monocytes in convalescent COVID-19 patients with an eye toward the potential implications for disease progression.
We show that the percentage of total monocytes is decreased in COVID-19 patients, with significant decreases in intermediate and resolution of symptoms vs. >30 days infection), vaccination status (not vaccinated vs. predominantly vaccinated), or possibly viral strain.One limitation of the present study is that it compares samples from a single time point during the convalescent phase of COVID-19 infection, two to four weeks after the resolution of symptoms.It is certainly possible that this study may not capture changes that would become evident in a more comprehensive longitudinal study that follows patients throughout the acute to convalescent phases of disease.
Samples were collected during the early phase of the COVID-19 pandemic and, therefore, likely represent a primary exposure to the initial strain (wild-type or lineage A) of SARS-CoV-2 present in the United States.Our findings suggest that the convalescent phase of infection with wild-type SARS-CoV-2 is associated with decreased monocytes, increased lymphocytes, and a hyporesponsive monocyte phenotype characterized by decreased expression of activation markers and proinflammatory cytokines in response to stimulation.The relevance of these findings to subsequent infections with SARS-CoV-2 variants of concern, such as Alpha, Beta, Gamma, Delta, and Omicron, is unknown.There are several differences in the humoral, cellular, and innate immune responses to these variants of concern (reviewed in (62).For example, the SARS-CoV-2 Alpha variant evades innate immune detection better than prior SARS-CoV-2 isolates, due at least in part to increased expression of ORF9B (63).Given these differences, it is possible that there are differences in monocyte function during the convalescent phase of disease.It will be important to determine whether the observed changes in monocyte frequency and function following infection with wild-type SARS-CoV-2 infection are _following infection with other SARS-CoV-2 variants.
Circulating monocytes are comprised of three phenotypically and functionally distinct subsets: classical monocytes, intermediate monocytes, and non-classical (64,65).Classical monocytes account for about 80-95% of circulating monocytes.These cells are highly phagocytic, and play major roles in innate immune responses, antibody-dependent cellular cytotoxicity (ADCC), and coagulation.Intermediate monocytes account for 2-10% of circulating monocytes.These cells are important producers of reactive oxygen species (ROS), in addition to processing and presenting antigen for T-cell stimulation.Non-classical monocytes account for about 2-10% of circulating monocytes.They are primarily responsible for clearance of debris and apoptotic cells, but also secrete inflammatory cytokines.Due to their varying abilities to phagocytose, process and present antigen, and produce proinflammatory cytokines, all three monocyte subtypes play a role during viral infection (65, 66).However, nonclassical monocytes are thought to play a primary role during the antiviral response due to their expression of pattern recognition receptors that recognize viral nuclei acids (67).We found that there were significant decreases in the relative levels of intermediate and non-classical monocytes in convalescent COVID-19 patients.Given their purported functions, their relative decrease may be associated with decreased T-cell activation and/or decreased proinflammatory cytokine production in convalescent patients.
In addition to finding that the percentage of monocytes was decreased in convalescent patients, we demonstrated that they were hyporesponsive to LPS stimulation.Classical monocytes from convalescent COVID-19 patients demonstrate significantly lower levels of CD56 expression in response to LPS stimulation compared to uninfected controls.This finding was not observed in intermediate or classical monocytes.In addition, classical monocytes from convalescent patients show no change in CD69 expression in response to LPS stimulation.Furthermore, monocytes from convalescent patients express significantly less TNF-a and IL-6 when treated with LPS.These findings suggest that, as patients transition from acute to convalescent stages of disease, monocytes shift towards a hyporesponsive phenotype.
The biological consequences of these changes in the frequencies of monocyte subtypes and monocyte function are unclear.It is possible that this shift to a hyporesponsive phenotype may play a role in dampening the inflammatory response and promoting tissue repair.Tolerogenic myeloid cells, in particular mDCs, have been shown to suppress inflammation in other settings by means of decreased T-cell activation (68).Recent studies have also demonstrated immune exhaustion in murine monocytes following stimulation (69, 70).These exhausted monocytes may play a role in immune suppression following inflammatory conditions (69), though data in human monocytes is lacking.Our studies did not delve into the mechanism(s) by which classical monocytes become hyporesponsive in the setting of convalescent COVID-19.Studies of monocytes and macrophages that become hyporesponsive in the setting of repeated LPS stimulation, exposure to commensal microbes, and systemic inflammation suggest roles for antiinflammatory cytokines (71), the downregulation of receptors such as TLR4 (72,73), epigenetic changes (74), and/or altered intracellular signaling cascades (75).It is possible that SARS-CoV-2 acts in a similar manner to promote a hyporesponsive phenotype in monocytes.The hyporesponsive nature of monocytes in convalescent COVID-19 patients may play a deleterious role in the immune response to subsequent bacterial infections.COVID-19 patients at increased risk for bacterial co-infections and superinfections, which are associated with adverse outcomes (76, 77).Interestingly, Smith et al. showed that there is a time-dependent increase in disease severity in a murine model of SARS-CoV-2 and bacterial superinfection (78).It is possible that this observed increase in disease severity correlates with decreased monocyte function as there was no increase in monocyte or macrophage recruitment to the lungs of mice co-infected with SARS-CoV-2 and pneumococcus compared to mice infected with SARS-CoV-2 alone.Finally, our findings in convalescent patients are similar to those reported in a cohort of long COVID patients (37).In that study, PBMCs from long COVID patients produced lower levels of proinflammatory cytokines compared to uninfected controls.It should be noted that other studies of long COVID patients have demonstrated a dysregulated immune response characterized by increased inflammation (33)(34)(35)(36).Despite these differences, our findings reinforce the notion that the immune response is dysregulated following SARS-CoV-2 infection and that this dysregulation may contribute to long COVID.
Consistent with prior publications (52-54), we found that stimulation with LPS led to changes in the relative proportions of classical, intermediate, and non-classical monocytes, with a decrease in the percentages of intermediate and non-classical monocytes and an increase in the percentage of classical (Supplementary Figure S4).This shift in the relative proportions of the monocyte subsets occurred in both healthy donors and convalescent COVID-19 patients.It has been proposed that intermediate monocytes may represent a transition state between non-classical and classical monocytes (79).If this is true, our findings suggest that LPS treatment may promote the transition from intermediate monocytes to classical monocytes, rather than to non-classical monocytes as is proposed to occur under steady state conditions (54).Additional considerations for the observed effects of LPS include decreased viability of intermediate and non-classical monocytes.
There is a correlation between expression of cell surface (57) and extracellular, vesicular (58) CD142 (tissue factor) and COVID-19 disease severity.Interestingly, in a study by Stephenson et al., circulating monocytes displaying the highest levels of ISG expression were found to express ligands and receptors for platelets (80).This may explain the increased propensity for coagulopathy in acutely ill COVID-19 patients.We found a significant decrease in classical monocytes expressing CD142 in response to LPS stimulation in convalescent patients compared to uninfected subjects.This finding is consistent with our data showing that classical monocytes from convalescent COVID-19 patients demonstrate significantly lower levels of CD56 and proinflammatory cytokines in response to LPS stimulation.
Our results indicate that there is a relative decrease in monocytes in convalescent COVID-19 patients following mild disease compared to control, uninfected subjects.Intermediate and non-classical monocytes are decreased in COVID-19 patients with no significant difference in classical monocytes.Furthermore, classical monocytes from COVID-19 patients demonstrate decreased CD56 expression and decreased CD142 expression in response to LPS stimulation compared to control subjects.Finally, monocytes from convalescent COVID-19 patients demonstrate significantly decreased TNF-a and IL-6 expression in response to LPS stimulation compared to control subjects.Taken together, these findings suggest that SARS-CoV-2 infection exhibits a clear effect on both monocyte subset development and the response to physiological stimuli, as reflected in their relative numbers, activation state, and function, which lasts into the convalescent phase of disease.
The COVID-19 patients ranged in age from 19 to 65 years old (43.3 y/o mean), representing different races and genders.The healthy control individuals ranged in age from 19 to 71 years old (38.5 y/o mean), representing different races and genders (Table

TABLE 1
Characteristics of study participants.

TABLE 1 Continued
b Data analyzed using Fisher's exact test (male vs. female).c Data analyzed using Fisher's exact test (white vs. non-white).d Data analyzed using Fisher's exact test (Non-Hispanic vs. Hispanic).